William Blair began coverage on shares of Phreesia (NYSE:PHR) in a report released on Monday, Briefing.com Automated Import reports. The brokerage issued an outperform rating on the stock.
Separately, Chardan Capital began coverage on Phreesia in a research note on Tuesday, July 23rd. They set a buy rating and a $33.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, Phreesia presently has a consensus rating of Buy and an average price target of $30.50.
Shares of NYSE PHR opened at $25.25 on Monday. Phreesia has a 1-year low of $23.00 and a 1-year high of $29.38.
In other Phreesia news, Director Scott Perricelli sold 743,388 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $18.00, for a total transaction of $13,380,984.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ii L.P. Chv sold 335,767 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $18.00, for a total value of $6,043,806.00. The disclosure for this sale can be found here.
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.
Further Reading: Gross Domestic Product (GDP)
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.